AzTrials
AzTrials

Neuralgia, PostherpeticPhase 2NCT00619476

A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)

A Phase 2 study testing GEn 1200mg/day, GEn 2400mg/day and GEn 3600mg/day in people with Neuralgia, Postherpetic, run by XenoPort, Inc. at 83 sites in 2 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Neuralgia, Postherpetic
What is being tested?
GEn 1200mg/day, GEn 2400mg/day and GEn 3600mg/day
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
376 participants
Where
83 sitesin 2 countries
Study dates
Feb 2008to Jul 2009
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • 18 years or older
  • Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use one a specified highly effective method for avoiding pregnancy
  • Documented medical diagnosis of PHN of with pain present for at least three months from the healing of a herpes zoster rash
  • Baseline 24-hour average pain intensity score ≥ 4.0 based on an 11-point PI-NRS
  • Provides written informed consent in accordance with all applicable regulatory requirements

Who cannot join

  • Other chronic pain conditions not associated with PHN. However, the subject will not be excluded if:
  • The pain is located at a different region of the body; and
  • The pain intensity is not greater than the pain intensity of the PHN; and
  • The subject can assess PHN pain independently of other pain
  • Is unable to discontinue prohibited medications or non-drug therapies or procedures throughout the duration of the study
  • Hepatic impairment defined as ALT or AST > 2x upper limit of normal (ULN), or alkaline phosphatase or bilirubin > 1.5x ULN
Show all 25Show fewer
  • Chronic hepatitis B or C
  • Impaired renal function defined as creatinine clearance <60 mL/min or requiring hemodialysis
  • Corrected QT (QTc) interval ≥ 450 msec or QTc interval ≥480 msec for patients with Bundle Branch Block
  • Uncontrolled hypertension at screen (sitting systolic >160 mmHg and/or sitting diastolic >90 mmHg)
  • Current diagnosis of active epilepsy or any active seizure disorder requiring chronic therapy with antiepileptic drugs
  • Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GEn, or, in the investigator's judgment
  • Is considered to be clinically significant and may pose a safety concern, or,
  • Could interfere with the accurate assessment of safety or efficacy, or,
  • Could potentially affect a subject's safety or study outcome
  • Meets criteria defined by the DSM-IV-TR for a major depressive episode or for active significant psychiatric disorders within last year
  • Depression in remission, with or without antidepressant treatment, may participate, unless stable antidepressant regimen is a prohibited medication
  • Antidepressant medication may not be changed or discontinued to meet entry criteria and must be stable for at least three months prior to enrollment
  • History of clinically significant drug or alcohol abuse (DSM-IV-TR) or is unable to refrain from substance abuse throughout the study. Benzodiazepines or atypical benzodiazepines as hypnotic sleep agents permitted.
  • Currently participating in another clinical study in which the subject is, or will be exposed to an investigational or non-investigational drug or device
  • Has participated in a clinical study and was exposed to investigational or non-investigational drug or device:
  • Within preceding month for studies unrelated to PHN, or
  • Within preceding six months for studies related to PHN
  • Treated previously with GEn
  • History of allergic or medically significant adverse reaction to investigational products (including gabapentin) or their excipients, acetaminophen or related compounds

Trial locations and contacts

83 sites in 2 countries.

83 sites in 2 countries

United States72 sites
  • GSK Investigational Site

    Albuquerque, New Mexico, 87108

  • GSK Investigational Site

    Altoona, Pennsylvania, 16602

  • GSK Investigational Site

    Amherst, New York, 14226

  • GSK Investigational Site

    Arcadia, California, 91007

  • GSK Investigational Site

    Bingham Farms, Michigan, 48025

  • GSK Investigational Site

    Birmingham, Alabama, 35205

  • GSK Investigational Site

    Boston, Massachusetts, 02215

  • GSK Investigational Site

    Boulder, Colorado, 80304

  • GSK Investigational Site

    Bradenton, Florida, 34203

  • GSK Investigational Site

    Bradenton, Florida, 34206

  • GSK Investigational Site

    Brooklyn, New York, 11235

  • GSK Investigational Site

    Chandler, Arizona, 85225

  • GSK Investigational Site

    Charlotte, North Carolina, 28204

  • GSK Investigational Site

    Chicago, Illinois, 60611

  • GSK Investigational Site

    Cincinnati, Ohio, 45246

  • GSK Investigational Site

    Danville, Indiana, 46122

  • GSK Investigational Site

    Daytona Beach, Florida, 32117

  • GSK Investigational Site

    Decatur, Georgia, 30033

  • GSK Investigational Site

    Elkhart, Indiana, 46514

  • GSK Investigational Site

    Eugene, Oregon, 97401

  • GSK Investigational Site

    Gilbert, Arizona, 85234

  • GSK Investigational Site

    Greensboro, North Carolina, 27408

  • GSK Investigational Site

    Hallandale, Florida, 33009

  • GSK Investigational Site

    Hickory, North Carolina, 28601

  • GSK Investigational Site

    High Point, North Carolina, 27262

  • GSK Investigational Site

    Hollywood, Florida, 33021

  • GSK Investigational Site

    Huntington Park, California, 90255

  • GSK Investigational Site

    Kansas City, Missouri, 64111

  • GSK Investigational Site

    Lebanon, New Hampshire, 03766

  • GSK Investigational Site

    Libertyville, Illinois, 60048

  • GSK Investigational Site

    Litchfield Park, Arizona, 85340

  • GSK Investigational Site

    Little Rock, Arkansas, 72205

  • GSK Investigational Site

    Marietta, Georgia, 30066

  • GSK Investigational Site

    Medford, Oregon, 97501

  • GSK Investigational Site

    Milwaukee, Wisconsin, 53226

  • GSK Investigational Site

    Naranja, Florida, 33032

  • GSK Investigational Site

    New Port Beach, California, 92660

  • GSK Investigational Site

    New Port Richey, Florida, 34652

  • GSK Investigational Site

    New York, New York, 10004

  • GSK Investigational Site

    New York, New York, 10128

  • GSK Investigational Site

    Norman, Oklahoma, 73071

  • GSK Investigational Site

    Northport, Alabama, 35476

  • GSK Investigational Site

    Northridge, California, 91325

  • GSK Investigational Site

    Ocala, Florida, 34471

  • GSK Investigational Site

    Oklahoma City, Oklahoma, 73112

  • GSK Investigational Site

    Olive Branch, Mississippi, 38654

  • GSK Investigational Site

    Oxnard, California, 93030

  • GSK Investigational Site

    Redondo Beach, California, 90277

  • GSK Investigational Site

    Reno, Nevada, 89502

  • GSK Investigational Site

    Riverside, California, 92506

  • GSK Investigational Site

    Rochester, New York, 14642

  • GSK Investigational Site

    Rockville, Maryland, 20852

  • GSK Investigational Site

    Salisbury, North Carolina, 28144

  • GSK Investigational Site

    San Antonio, Texas, 78238

  • GSK Investigational Site

    San Diego, California, 92117

  • GSK Investigational Site

    San Francisco, California, 94109

  • GSK Investigational Site

    Santa Monica, California, 90404

  • GSK Investigational Site

    Scottsdale, Arizona, 85251

  • GSK Investigational Site

    Shreveport, Louisiana, 71101

  • GSK Investigational Site

    St Louis, Missouri, 63117

  • GSK Investigational Site

    St. Petersburg, Florida, 33702

  • GSK Investigational Site

    Tacoma, Washington, 98405

  • GSK Investigational Site

    Tallahassee, Florida, 32308

  • GSK Investigational Site

    Tampa, Florida, 33603

  • GSK Investigational Site

    Tampa, Florida, 33607

  • GSK Investigational Site

    Tampa, Florida, 33612

  • GSK Investigational Site

    Terre Haute, Indiana, 47802

  • GSK Investigational Site

    Tucson, Arizona, 85741

  • GSK Investigational Site

    Weber City, Virginia, 24290

  • GSK Investigational Site

    Wenatchee, Washington, 98801

  • GSK Investigational Site

    Winston-Salem, North Carolina, 27103

  • GSK Investigational Site

    Yakima, Washington, 98902

Other trials in United States

Canada11 sites
  • GSK Investigational Site

    Brampton, Ontario, L6T 3J1

  • GSK Investigational Site

    Kelowna, British Columbia, V1Y 3G8

  • GSK Investigational Site

    London, Ontario, N5Y 5K7

  • GSK Investigational Site

    Montreal, Quebec, H2K 4L5

  • GSK Investigational Site

    Niagara Falls, Ontario, L2E 6A6

  • GSK Investigational Site

    Québec, Quebec, G1V 4G2

  • GSK Investigational Site

    Saint Romuald, Quebec, G6W 5M6

  • GSK Investigational Site

    Sherbrooke, Quebec, J1H 4J6

  • GSK Investigational Site

    Thornhill, Ontario, L4J 6W6

  • GSK Investigational Site

    Toronto, Ontario, M9W 4L6

  • GSK Investigational Site

    Trois-Rivières, Quebec, G8T 7A1

Other trials in Canada

About this study

Official title: Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)

The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).

Read the detailed description

The primary purpose of study PXN110748 was to evaluate efficacy and safety of 3 fixed doses of GEn in the treatment of PHN.

Being tested
GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Placebo
Keywords
Neuropathic Pain, Post-herpetic neuralgia, PHN
Medical subject headings
Neuralgia, Postherpetic, Neuralgia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • GEn 1200mg/dayDrug

    Also called XP13512/GSK1838262, gabapentin enacarbil

    gabapentin enacarbil 1200mg/day

  • GEn 2400mg/dayDrug

    Also called XP13512/GSK1838262, gabapentin enacarbil

    gabapentin enacarbil 2400mg/day

  • GEn 3600mg/dayDrug

    Also called gabapentin enacarbil, XP13512/GSK1838262

    gabapentin enacarbil 3600mg/day

  • PlaceboDrug

    placebo

Study groups in NCT00619476
Study groupRoleWhat they receive
PlaceboPlacebo comparatorplacebo
Receives: Drug: Placebo
GEn 1200mg/dayExperimentalgabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks
Receives: Drug: GEn 1200mg/day
GEn 2400mg/dayExperimentalgabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks
Receives: Drug: GEn 2400mg/day
GEn 3600mg/dayExperimentalgabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks
Receives: Drug: GEn 3600mg/day

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data

    Baseline and EOMT values are the calculated means of the daily 24-hour API scores for each participant during the last 7 days prior to randomization (Baseline) and the earliest date of Week 13 visit/Withdrawal visit/last dose of study drug (EOMT). Participants used a hand-held diary to rate their average pain intensity over the preceding 24 hours, using an 11-point PI-Numerical Rating Scale (0=no pain, 10=pain as bad as you can imagine). LOCF was used if less than 4 days of diary data were provided. Change from baseline was calculated as EOMT score minus Baseline score.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

Secondary outcomes (18)
  1. Change From Baseline in the Mean Night-time Average Pain Intensity (API) Score at EOMT Using LOCF Data

    Night-time is defined as the time between going to bed at night and rising in the morning. Participants recorded night-time API on a daily basis in the morning upon awakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline wss calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  2. Change From Baseline in the Mean Current Morning Pain Intensity Score at EOMT Using LOCF Data

    Current pain is defined as the participant's assessment of pain intensity "right now." Participants recorded their current morning pain intensity in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  3. Change From Baseline in the Mean Night-time Worst Pain Intensity Score at EOMT Using LOCF Data

    Night-time worst pain is defined as the participant's assessment of their worst pain between going to bed at night and rising in the morning. Participants recorded night-time worst pain in the morning upon awakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  4. Change From Baseline in the Mean Sleep Interference Score at EOMT Using LOCF Data

    Participants assessed sleep interference due to pain on a daily basis using the 11-point NRS (0=pain does not interfere with sleep, 10=pain completely interferes with sleep). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  5. Change From Baseline in the Mean Day-time Average Pain Intensity(API) Score at EOMT Using LOCF Data

    Day-time is defined as the time between rising in the morning and going to bed at night. Participants recorded day-time API on a daily basis in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  6. Change From Baseline in the Mean Current Evening Pain Intensity Score at EOMT Using LOCF Data

    Current pain is defined as the participant's assessment of pain intensity "right now." Participants recorded their current evening pain intensity in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  7. Change From Baseline in the Mean Day-time Worst Pain Intensity Score at EOMT Using LOCF Data

    Day-time worst pain is defined as the participant's assessment of their worst pain between rising in the morning and going to bed at night. Participants recorded day-time worst pain in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  8. Change From Baseline in Pain Quality as Assessed by the Neuropathic Pain Scale (NPS) Summary Scores at EOMT Using LOCF Data

    The NPS assesses pain qualities and consists of 11-items, 10 assessed on an 11-point NRS (0=no impact to 10=greatest impact); and 1 open-ended question not used in score calculation. 4 summary scores are calculated: NPS 10 (items 1-7, 9-11), NPS 8 (8 pain descriptor items), NPS Non-Allodynic (NA) (8 NA items), and NPS 4 (4 pain quality items); and range from 0 to 100 (0=no impact and 100=greatest impact). The analysis is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  9. Change From Baseline in Pain Characteristics and Intensity as Assessed by the Short Form-McGill Pain Questionnaire (SF-MPQ) at EOMT Using LOCF Data

    The SF-MPQ, a general pain instrument, assesses the characteristics and intensity of pain and consists of 15-items assessed on a 4-point scale (0=none, 1=mild, 2=moderate, and 3=severe). 3 summary scores are calculated: sensory score (sum of items 1-11, range 0-33), affective score (sum of items 12-15, range 0-12), total score (sum of items 1-15, range 0-45), where lower scores = lower pain/impact. Analysis is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  10. Change From Baseline in Dynamic Allodynia at EOMT Using LOCF Data

    Dynamic allodynia (pain in response to a standardized light touch stimulus, a foam brush applied with light pressure to the site of maximum pain) was assessed by an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  11. Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) Questionnaire at EOMT Using LOCF Data

    The PGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the participant's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of "very much improved" or "much improved." EOMT response is defined as the score recorded at the Week13/Withdrawal visit.

    Measured: EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  12. Number of Participants Achieving Various Levels of Percent Reduction From Baseline in the Mean 24-hour Average Pain Intensity Score at EOMT Using LOCF Data

    Baseline and EOMT scores are the calculated means of the 24-hour average pain scores for each participant during the last 7 days prior to randomization and EOMT, respectively. Percent reduction from baseline was calculated as the [(EOMT score minus the baseline score)divided by the baseline score], multiplied by 100. The PI-NRS is an 11-point scale (0=no pain, 10=pain as bad as you can imagine) by which a participant assesses their 24-hour average pain intensity.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  13. Time to Onset of Sustained Improvement in the 24-hour Average Pain Intensity Score

    Sustained improvement in the 24-hour average pain intensity score is defined as at least 2 consecutive days on which the 24-hour average pain intensity score is >=2 points less than the mean 24-hour average pain intensity score at baseline. Time to onset is measured from baseline and was calculated as the first day of event minus the last day of baseline and is expressed in days. Baseline score is the calculated mean of the 24-hour average pain score for each participant during the last 7 days prior to randomization.

    Measured: Anytime post-baseline until date of last dose of study medication (up to Week 13)

  14. Change From Baseline in the Mean Daily Dose in Milligrams of Rescue Medication at EOMT Using LOCF Data

    Mean daily use of rescue medication (milligrams of acetaminophen) was calculated by determining the average number of tablets taken per day of rescue medication (Commerical Tylenol) during treatment and multiplying that by 500 mg. Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.

    Measured: Baseline and EOMT (Week 13 or early withdrawal)

  15. Change From Baseline in Severity of Pain and the Impact of Pain as Assessed by the Brief Pain Inventory (BPI) at EOMT Using LOCF Data

    The BPI, a general pain instrument, assesses the severity and interference of pain; and consists of 6 items assessed on an 11-point NRS (0=no impact and 10=greatest impact). 2 summary scores are calculated: BPI Severity Score (average of first 4 items) and BPI Interference Score (average of 7 responses to item 6); where each summary score ranges from 0 to 10 (0=no impact and 10=greatest impact). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  16. Change From Baseline in Quality of Life as Assessed by the SF-36 at EOMT Using LOCF Data

    The SF-36 is a general health-related quality of life instrument consisting of 36 items with various response options (Yes/No, 5- to 6-point Likert scale). Summary scores are calculated for 8 domains and 2 components (physical and mental); where scores range from 0 to 100 (higher scores = better quality of life). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  17. Change From Baseline in Emotional Functioning as Assessed by the POMS-B at EOMT Using LOCF Data

    The POMS-B, an emotional functioning instrument, assesses mood, tension, and other psychological symptoms and consists of 30-items assessed on a 5-point scale (0=not at all to 4=extremely). 6 summary scores are calculated: Tension/Anxiety, Depression/Rejection, Anger/Hostility, Vigor/Activity, Fatigue/Inertia, and Confusion/Bewilderment; and range from 0-20 (higher scores = more negative mood state). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.

    Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

  18. Number of Participants Who Are Responders on the Clinician Global Impression of Change (CGIC) Questionnaire at EOMT Using LOCF Data

    The CGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the clinician's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of "very much improved" or "much improved." EOMT response is defined as the score recorded at the Week13/Withdrawal visit.

    Measured: EOMT (representing the earliest date of Week 13 visit/withdrawal visit)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted21 Feb 2008 (estimated)
  2. Study startFeb 2008
  3. Primary completionJul 2009
  4. Study completionJul 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
376 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00619476
Sponsor's protocol ID
110748
Status last verified
Jan 2013
First submitted
7 Feb 2008
Last updated
22 Jul 2013
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing GEn 1200mg/day, GEn 2400mg/day and GEn 3600mg/day in people with Neuralgia, Postherpetic, run by XenoPort, Inc. at 83 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 83 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 May 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data (time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in